Safety and efficacy of peptide receptor radionuclide therapy in treating high-risk patients with extensive neuroendocrine tumors

被引：0
|
作者：
Alsadik, S. R. [1 ]
Gnanasegaran, G. [1 ]
Chen, L. [1 ]
Toumpanakis, C. [1 ]
Caplin, M. [1 ]
Navalkissoor, S. [1 ]
机构：
[1] Royal Free Hosp, London, England
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2021年 / 33卷
关键词：
neuroendocrine tumor; net; peptide receptor radionuclide therapy prrt; 1771u-dotatate; extensive liver metastases; extensive skeletal metastases; extensive tumor burden;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
K05
引用
收藏
页码：172 / 172
页数：1
相关论文
共 50 条
  • [11] Peptide Receptor Radionuclide Therapy An emrirciing treatment for gastrointestinal neuroendocrine tumors
    Myers, Adria
    Chitwood, Holly Renea
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2020, 24 (02) : 129 - 133
  • [12] Plasma Markers for Therapy Response Monitoring in Patients with Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy
    Wetz, Christoph
    Ruhwedel, Tristan
    Schatka, Imke
    Grabowski, Jane
    Jann, Henning
    Metzger, Giulia
    Galler, Markus
    Amthauer, Holger
    Rogasch, Julian M. M.
    Guntinas-Lichius, Orlando
    CANCERS, 2023, 15 (24)
  • [13] Efficacy and safety of peptide receptor radionuclide therapy (PRRT) in patients with chronic kidney disease (CKD)
    Alsadik, S. R.
    Gnanasegaran, G.
    Chen, L.
    Toumpanakis, C.
    Caplin, M.
    Navalkissoor, S.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 170 - 170
  • [14] The Use of Peptide Receptor Radionuclide Therapy in Patients With Neuroendocrine Tumor Cardiac Metastases
    Yu, Irene S.
    Funk, Gayle
    Lin, Eugene
    Kennecke, Hagen F.
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (01) : e23 - e26
  • [15] Evaluation of Toxicity in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors (NET)
    Duan, H.
    Girod, B.
    Ninatti, G.
    Ferri, V
    Kunz, P.
    Fisher, G.
    Moradi, F.
    Davidzon, G.
    Franc, B.
    Lagaru, A.
    Aparici, Mari C.
    NEUROENDOCRINOLOGY, 2020, 110 : 252 - 252
  • [16] Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors
    Santo, Giulia
    di Santo, Gianpaolo
    Cicone, Francesco
    Virgolini, Irene
    JOURNAL OF NEUROENDOCRINOLOGY, 2025, 37 (03)
  • [17] The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors
    Bodei, Lisa
    Cwikla, Jaroslaw B.
    Kidd, Mark
    Modlin, Irvin M.
    JOURNAL OF THORACIC DISEASE, 2017, 9 : S1511 - S1523
  • [18] A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
    Kasi, Pashtoon Murtaza
    Maige, Catherine L.
    Shahjehan, Faisal
    Rodgers, Jessica M.
    Aloszka, Debora L.
    Ritter, Ashton
    Andrus, Margaret L.
    Mcmillan, Jessica M.
    Mody, Kabir
    Sharma, Akash
    Jain, Manoj K.
    FRONTIERS IN ONCOLOGY, 2019, 8
  • [19] Factors contributing to tumor shrinkage after peptide receptor radionuclide therapy in patients with unresectable neuroendocrine tumors
    Noritoshi, K.
    Sho, H.
    Wild, D.
    Kaul, F.
    Motokazu, S.
    Naoki, O.
    Risa, F.
    Akihiro, S.
    Motohiko, T.
    Shoko, T.
    Yasushi, I
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 201 - 201
  • [20] Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy
    Cordero-Hernandez, Igryl S.
    Ross, Alicia C.
    Dasari, Arvind
    Halperin, Daniel M.
    Chasen, Beth
    Yao, James C.
    ENDOCRINE-RELATED CANCER, 2024, 31 (04)
12345